Human Stem Cells Institute OJSC (HSCI) is a Russian public biotech company founded in 2003.

HSCI is engaged in drug discovery, R&D and marketing of innovative proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy and biopharmaceutics.

The Company aims to foster a new culture of medical care – developing new health care opportunities in such areas as personalized and preventive medicine.

HSCI owns the largest family cord blood stem cell bank in Russia – Gemabank, as well as the reproductive cell and tissue bank Reprobank (personal storage and donation).

The Company launched Neovasculgen®, the first-in-class gene-therapy drug for treating Peripheral Arterial Disease, including Critical Limb Ischemia, and also introduced the innovative cell technology SPRS-therapy, which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.

HSCI is implementing a socially significant project to create its own Russia-wide network of Genetico medical centers & testing lab to provide a range of genetic diagnostic and consulting services with the aim of early identification, prediction and prophylactic treatment of genetic disorders (incl. PGD and NIPT among others).

The Company actively promotes its products on the Russian market and intends to open new markets throughout the world.

HSCI is listed on the Innovation & Investment Market (iIM) of the Moscow Exchange (ticker ISKJ). The Company conducted its IPO in December 2009, becoming the first Russian biotech company to go public.

Ask a question

Cell technologies for aging skin rejuvenation: the LAVIV therapy in the USA and the SPRS therapy in Russia

Cell technologies represent one of the regenerative medicine directions. The main goal of regenerative medicine is to restore lost structures and functions (as a result of diseases, traumas, aging, etc.) in the human body. Cell technologies are based on the use of viable cells, either autologous (patient's own cells) or allogenic (obtained from the other human tissues).

The main cell technology that is currently applied in cosmetology (both in Russia and abroad) is the use of autologous (i.e., patient's own) dermal fibroblasts to correct the age-related and other structural skin changes. Briefly, the technology is based on the following procedure: a small sample of patient's skin is used to obtain cultivated autologous fibroblasts which are intracutaneously injected into a patient.

The fibroblasts injected into the skin efficiently correct the age-related skin changes since after transplantation they intensively produce collagen, elastin, and the other essential components required for skin youth. As a result, the skin microstructure is restored, the skin density and elasticity is increased, the depth and amount of wrinkles is decreased, and the face color and contour is improved.

In Russia this technology is termed "the SPRS therapy." It has been developed by qualified specialists at the Human Stem Cell Institute (the Roszdravnadzor certificate N2009/308 of July 2010) in Russia. In the USA, a similar technology which is termed "the LAVIV therapy" has been developed by Fibrocell Science, an American company (the FDA license of June 2011).

  • Hyaluronic acid: for those who take risk
  • What is the SPRS therapy and how does it fight skin aging?
  • Botox. Poison and current for face skin
  • How many the SPRS procedures should one take to achieve the optimal result? How often must they be repeated?
  • What is the cost of the SPRS therapy course?